Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Healthcare regulator National Medical Products Administration approved Innovent Biologics' drug Jaypirca for treating chronic ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms. Targeted therapies, such as BTK and BCL-2 inhibitors, are common treatments ...

Innovent Biologics, Inc. announced that the China National Medical Products Administration (?NMPA?) has approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine ...

Treatments for the most common form of adult leukemia, chronic lymphocytic leukemia (CLL), have changed dramatically over the past decade. Today, patients have the possibility to be treated with ...

Financing round of 12 million closed, including grant funding, led by SPRIND (the German Federal Agency for Breakthrough Innovation) and Huma, with participation from private ...

Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without needing treatment, while another may develop rapidly progressing disease. In a ...

What to choose after a drug stops workingIn the treatment of blood cancers, a drug that was initially very effective may stop ...

Discover essential information about Chronic Lymphocytic Leukemia (CLL), its diagnosis, symptoms, and treatment options in ...